The most operationally important sentence about the Bundibugyo Ebola outbreak this week did not come from the WHO, Africa CDC, or any health ministry. It came from Shanelle Hall in a PBS NewsHour interview: there is no Bundibugyo virus vaccine being actively considered for procurement. The Africa CDC's Saturday continental-security declaration, which named ten at-risk countries by name in Kampala, and the WHO's May 16 PHEIC determination, posted to social media as 246 suspected cases and 80 deaths [1], both operate inside the same procurement vacuum. The structural answer to a week of questions about what the Sabin Vaccine Institute, CEPI, BARDA, or any frontier vaccine sponsor was preparing in response to a confirmed Bundibugyo virus outbreak that has now crossed two countries is: nothing in the procurement pipeline that is "actively considered."

By Monday Day 10 the operational numbers had advanced. Africa CDC's May 18 declaration of the outbreak as a Public Health Emergency of Continental Security cited approximately 395 suspected cases and 106 associated deaths across the Democratic Republic of the Congo (mainly in the Mongbwalu, Rwampara, and Bunia Health Zones in Ituri Province) and Uganda (Kampala, where two cases and one death had been reported). [2] The DRC Ministry of Health declared its 17th Ebola outbreak on May 15, with Bundibugyo virus species confirmed by genomic sequencing at the Institut National de Recherche Biomédicale (INRB) in Kinshasa. [3] The Uganda Ministry of Health confirmed Bundibugyo virus disease the same day, identifying an imported fatal case from a patient who had traveled from Bunia, DRC, to Kampala for medical care. [3] A second imported case in Kampala was confirmed May 16 with no apparent link to the first. [4]

The WHO's Director-General Tedros declared the outbreak a Public Health Emergency of International Concern on May 16 after consulting with the affected states-parties under the 2005 International Health Regulations. [4] The CDC issued a Level 1 Travel Health Notice for Uganda and a Level 3 Travel Health Notice for the DRC on May 15. [4] The U.S. Centers for Disease Control's Health Alert Network notice posted to clinicians, public health practitioners, and travelers states that "the risk of spread to the United States is considered low at this time," and lists Bundibugyo's symptom presentation (fever, generalized body pain, weakness, vomiting, and in some cases bleeding) along with the standard infection-control protocols. [4] The Australian Centre for Disease Control's situation report 1, issued May 18, assesses the risk to Australia as low. [5]

The structural problem the Africa CDC declaration foregrounds is that Bundibugyo virus (species Orthoebolavirus bundibugyoense) is one of four Ebola viruses for which no approved vaccine exists. The Ervebo and Zabdeno-Mvabea vaccines licensed for the Zaire ebolavirus species do not protect against Bundibugyo. The previous Bundibugyo outbreaks — the 2007 outbreak in Bundibugyo, Uganda (which gave the virus its name) and the 2012 outbreak in Isiro, DRC — were small enough that no vaccine procurement pipeline matured. The current outbreak, with 395 suspected cases and 106 associated deaths across two countries inside ten days [2], is structurally larger than either earlier outbreak at the same point in its timeline. The Sabin Vaccine Institute, the Coalition for Epidemic Preparedness Innovations (CEPI), and the U.S. Biomedical Advanced Research and Development Authority (BARDA) are the typical institutional answers to "who is moving on a vaccine candidate." Sunday's brief carried the PAHO Day 2 epi-alert; Sunday's other brief confirmed Sabin had no Bundibugyo breakthrough as of Saturday.

The Hall PBS quote — "no vaccine being actively considered" — is the structural reading of the procurement-ledger negative space. Hall, formerly UNICEF's chief of supply, is the person who would credibly know whether any sponsor had moved a Bundibugyo candidate into the actively-considered category since the May 15 outbreak confirmation. Her quote names what the institutional silence had not. The lost-science thread the paper has carried since the spring tracks two structural patterns: a U.S. government withdrawal from the WHO and 90 percent USAID funding cut [6] reduces the demand-side pull for vaccine candidates against pathogens that primarily affect African populations; the absence of approved Bundibugyo vaccines after a 19-year clock since the 2007 outbreak reflects the supply-side absence of a sustained procurement pipeline. The current outbreak is testing whether either side responds inside the operational window. As of Monday morning, neither has. Africa CDC and WHO have mobilized $2.5 million for the response [6]; the United States, withdrawn from the WHO and with USAID's Bundibugyo-relevant programs cut, is not on the donor list at write time.

The community refusal-of-quarantine pattern the paper has tracked through the week is unchanged: two clinic attacks in 48 hours, eighteen patients fled isolation. No third clinic attack has surfaced through Sunday evening. The fled patients have not been confirmed recovered. The contact-tracing infrastructure in Ituri province operates inside what the WHO calls insecurity and movement restrictions; "follow-up remains weak" and "several listed contacts became symptomatic and died before they could be isolated." [3] The Mongbwalu Health Zone is described by the WHO as a high-traffic mining area; the suspected index case is a health worker who developed symptoms April 24 and died at a Bunia medical centre. [5] The first known suspected case predates the May 15 outbreak confirmation by three weeks. The structural retrospective question is how many transmission chains were established before laboratory testing identified the pathogen.

The DRC World Cup window — the Houston Congo soccer team's June 17 vs Portugal match — is the next operational test of the Title 42 widening posture. Yahoo Sports' Sunday reporting that the DRC is "expected to receive exemption" from the widened travel ban graduates the question from a binary cliffhanger to a structural test of whether the exemption arrives in writing before June 17. WHO Director-General Tedros's Title-42-specific silence reaches Day 9 on Monday. Tedros broke the broader PHEIC-related silence Saturday by confirming three new Uganda cases and raising the DRC risk to "very high" [1]; the silence on U.S. travel-ban widening remains intact. The institutional triangle (U.S. widened, Africa CDC rebuked and operationalized, WHO silent on U.S. specifically) holds with refinement.

The unresolved questions for Tuesday: whether Tedros breaks the Title-42 specific silence Monday or Tuesday; whether the DRC exemption from the travel-ban widening arrives formally rather than as expectation; whether a third clinic attack occurs; whether the 18 fled patients are recovered or surface as new transmission chains; whether the Sabin/CEPI/BARDA pipeline produces any Monday commitment in response to the Hall quote; whether the Lancet, Nature, or another peer-reviewed venue accelerates publication of any candidate Bundibugyo vaccine paper that might be in the pipeline but not actively considered for procurement. The Africa CDC's leadership in declaring the PHECS — the first such declaration since the body acquired the statutory authority — is itself a structural artifact. Continental institutions are operating; international institutions are operating; vaccine sponsors are not. The paper's read of Day 10 is that the institutional declarations are doing what they can do, and that they cannot substitute for procurement decisions that have not been made.

The position the paper carries forward: the structural answer to "what is being done about a vaccine" is "nothing actively considered"; the structural answer to "what is being done about the outbreak" is the Africa CDC declaration, the WHO PHEIC, and the on-the-ground response in Ituri province operating inside insecurity and population displacement. Both answers are correct simultaneously. Both are inadequate to the operational situation. The Hall quote is the one this paper will repeat as long as it remains accurate.

-- NORA WHITFIELD, Chicago